A bold truth about cannabis policy could reshape how seniors access care, change the research landscape, and alter stock trajectories. That’s the core issue now front and center as discussions about reclassifying pot and CBD move toward a potential executive order. If implemented, the plan would broadly expand access to cannabis products and possibly redefine what counts as legitimate medical treatment for the elderly.
President Donald Trump is reportedly leaning toward signing an executive order that would reclassify cannabis as a Schedule III substance under the DEA. That shift would place cannabis closer to common pain-relievers like Tylenol with codeine, rather than keeping it in the most restrictive Schedule I category that includes heroin and LSD. The order would also open the door to a Medicare pilot program designed to cover cannabis-derived products for seniors.
Observers from the cannabis industry, legal practice, and medical research anticipate meaningful consequences for consumers and for health-care providers. The rollout is expected to focus on cannabidiol products—CBD—that target chronic pain, sleep issues, and other conditions relevant to aging, according to Shawn Hauser, a partner at Vicente LLP, a firm specializing in cannabis law.
CBD’s rise has been meteoric, moving from niche markets into mainstream products such as ready-to-drink beverages and personal care items. Yet federal regulators remain cautious, and broad regulatory endorsement has not yet arrived. Hauser notes that the executive order would likely specify which cannabinoids qualify and require that they come from federally legal sources.
Even as many insiders view reclassification as a likely step forward, the Medicare angle introduces a notable complication. If seniors could be reimbursed for cannabis products, the health-care system could become more deeply entwined with cannabis-derived therapies, even in the absence of extensive clinical proof for all claimed benefits.
Industry insiders expect the final order to outline definitions for legal cannabinoids, the required administrative mechanisms, and a framework for oversight by the FDA. Trump signaled that reclassification could unlock extensive research opportunities that are currently hindered by the Schedule I status, hinting that the administration is taking the research barrier seriously.
From an investment standpoint, moving to Schedule III and enabling Medicare coverage could unleash fresh institutional capital. Timothy Seymour of Seymour Asset Management puts it plainly: with insurance and liquidity more readily available, sector valuations could rise substantially, potentially doubling or tripling in the long run.
The push comes amid data suggesting shifting consumer behavior: a 2024 analysis of 40 years of data from Carnegie Mellon University found more Americans using marijuana daily than drinking alcohol at the same frequency for the first time. This trend underscores potential demand for broader, more legitimate access channels.
Supporters like Howard Kessler, a longtime Trump ally who leads The Commonwealth Project, lobby for a Medicare pilot as a pragmatic way to collect real-world data on safety and outcomes for seniors. They argue this bypasses years of traditional FDA trials while still offering structured evaluation.
However, the Medicare proposal has its critics, including some Trump allies wary of cost and liability. House Speaker Mike Johnson has questioned the fiscal impact and potential risks of reimbursing non-FDA-approved treatments, and FDA officials caution that reimbursing cannabis-based therapies without established agency approval would be unprecedented.
Scientific consensus on medical cannabis remains debated. The FDA has approved Epidiolex—CBD-based medication—for select epilepsy cases, illustrating cautious progress rather than broad endorsement. Critics argue that a Medicare pilot could expose seniors to therapies lacking rigorous evidence, and some studies highlight potential liver toxicity or interactions with other medications when CBD is used long-term.
Beyond politics, research on cannabis’s clinical effectiveness is mixed. A 2023 review of 134 studies involving adults 50 and older found inconsistent benefits for conditions such as advanced cancer and dementia, and noted harms like depression, anxiety, cognitive changes, and physical injuries. Such findings reinforce the view that robust, high-quality trials are essential to guide medical use.
Nevertheless, rescheduling cannabis could substantially lower barriers to clinical research. Johns Hopkins researcher Ryan Vandrey notes that Schedule I status has impeded large, well-controlled trials, leaving policymakers to make decisions with limited data.
For investors, the specifics of any rescheduling are crucial. A Schedule III reclassification would ease banking and tax constraints that currently hamper cannabis businesses, opening the door to standard corporate finance practices and potentially more robust liquidity.
Market dynamics already reflect growing appetite: last year’s data from the USDA show a notable rise in U.S. cannabis production value, while the global market for cannabis-derived products is projected to reach about $160 billion by 2032. Positive chatter around possible rescheduling helped lift the stock prices of major producers like Tilray Brands and Canopy Growth in the short term.
Medicare coverage could become a powerful accelerant for consolidation as larger players chase scale and credentialed credibility. Seymour suggests that smaller, profitable firms could become acquisition targets as the sector reorganizes around a federally supported framework. Large pharmaceutical firms may increasingly peer at cannabis as a potential area for collaboration or competition, especially if federal eligibility expands.
Industry leaders anticipate a future where more players, including national pharmacy chains, participate in cannabis distribution if reimbursement and regulatory barriers ease. Yet this evolution could also intensify rivalry with traditional pharma and prompt heightened scrutiny over efficacy and safety.
The debate continues to hinge on balancing patient access and safety with scientific rigor and prudent policy. What is your view on treating cannabis-derived therapies as standard medical options for seniors, and should federal coverage come with strict, evidence-based guidelines or a broader, real-world data approach? Share your thoughts in the comments.
